Integrative strategy of testing systems for identification of endocrine disruptors inducing metabolic disorders-an introduction to the OBERON project

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Audouze, Karine
• dc.contributor.author Sarigiannis, Denis
• dc.contributor.author Alonso Magdalena, Paloma
• dc.contributor.author Brochot, Celine
• dc.contributor.author Casas Sanahuja, Maribel
• dc.contributor.author Vrijheid, Martine
• dc.contributor.author Babin, Patrick J.
• dc.contributor.author Karakitsios, Spyros
• dc.contributor.author Coumoul, Xavier
• dc.contributor.author Barouki, Robert
• dc.date.accessioned 2021-02-09T07:04:17Z
• dc.date.available 2021-02-09T07:04:17Z
• dc.date.issued 2020
• dc.description.abstract Exposure to chemical substances that can produce endocrine disrupting effects represents one of the most critical public health threats nowadays. In line with the regulatory framework implemented within the European Union (EU) to reduce the levels of endocrine disruptors (EDs) for consumers, new and effective methods for ED testing are needed. The OBERON project will build an integrated testing strategy (ITS) to detect ED-related metabolic disorders by developing, improving and validating a battery of test systems. It will be based on the concept of an integrated approach for testing and assessment (IATA). OBERON will combine (1) experimental methods (in vitro, e.g., using 2D and 3D human-derived cells and tissues, and in vivo, i.e., using zebrafish at different stages), (2) high throughput omics technologies, (3) epidemiology and human biomonitoring studies and (4) advanced computational models (in silico and systems biology) on functional endpoints related to metabolism. Such interdisciplinary framework will help in deciphering EDs based on a mechanistic understanding of toxicity by providing and making available more effective alternative test methods relevant for human health that are in line with regulatory needs. Data generated in OBERON will also allow the development of novel adverse outcome pathways (AOPs). The assays will be pre-validated in order to select the test systems that will show acceptable performance in terms of relevance for the second step of the validation process, i.e., the inter-laboratory validation as ring tests. Therefore, the aim of the OBERON project is to support the organization for economic co-operation and development (OECD) conceptual framework for testing and assessment of single and/or mixture of EDs by developing specific assays not covered by the current tests, and to propose an IATA for ED-related metabolic disorder detection, which will be submitted to the Joint Research Center (JRC) and OECD community.
• dc.description.sponsorship The authors would like to acknowledge OBERON (https://oberon-4eu.com/, a project funded by the European Union’s Horizon 2020 research and innovation program under grant agreement no. 825712.
• dc.format.mimetype application/pdf
• dc.identifier.citation Audouze K, Sarigiannis D, Alonso-Magdalena P, Brochot C, Casas M, Vrijheid M, Babin PJ, Karakitsios S, Coumoul X, Barouki R. Integrative strategy of testing systems for identification of endocrine disruptors inducing metabolic disorders-an introduction to the OBERON project. Int J Mol Sci. 2020; 21(8):2988. DOI: 10.3390/ijms21082988
• dc.identifier.doi http://dx.doi.org/10.3390/ijms21082988
• dc.identifier.issn 1422-0067
• dc.identifier.uri http://hdl.handle.net/10230/46393
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Int J Mol Sci. 2020; 21(8):2988
• dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/825712
• dc.rights © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Adverse outcome pathways
• dc.subject.keyword Computational systems toxicology
• dc.subject.keyword Endocrine disruptors
• dc.subject.keyword Integrative approach
• dc.subject.keyword Metabolic disorders
• dc.subject.keyword Metabolism
• dc.subject.keyword Non-alcoholic fatty liver diseases
• dc.subject.keyword Non-animal testing; obesity
• dc.subject.keyword Predictive toxicology
• dc.title Integrative strategy of testing systems for identification of endocrine disruptors inducing metabolic disorders-an introduction to the OBERON project
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion